Efremova Yu.E., Kaftanov A.N., Gavrilov D.V., Arutyunov G.P.
Background: arterial hypertension (AH) is a leading modifiable risk factor of cardiovascular diseases. In the Russian Federation, a new Long and Active Life National Project intended to achieve expected 78-year life time by 2030 will be implemented in 2025-2030. To achieve the goal in hypertension patients, appropriate blood pressure control is necessary to reduce a risk of cardiovascular complications.
Aim: to study efficiency of combined use of azilsartan medoxomil + amlodipine vs. perindopril + amlodipine in AH patients in real clinical practice with regard to the risk of cardiovascular events.
Materials and Methods: an observational retrospective study was conducted using data from electronic medical records of AH patients who were divided into 2 groups depending on a therapy regimen: azilsartan medoxomil + amlodipine (Group 1) or perindopril + amlodipine (Group 2). The average follow-up duration was 11±13.4 months. A primary composite endpoint (5-major inverse cardiovascular events, 5-MACE) and secondary endpoints were evaluated.
Results: it was shown that a number of adverse events related to the primary composite endpoint (5-MACE) in the Group 2 was higher than that in the Group 1 (104 [11.8%] vs. 74 [8.4%], respectively [p=0.02]). Incidence of the secondary endpoint-related events did not differ significantly between the groups. The composite endpoint (5-MACE)-related outcome odds in the Group 1 were 1.4 times lower than those in the Group 2 (odd ratio: 0.69, 95% CI [0.5—0.94]).
Conclusion: a comparative study of the clinical outcome incidence in hypertension patients, depending on a combined therapy option, was conducted for the first time in the Russian Federation. As compared to perindopril+amlodipine therapy, azilsartan medoxomil+amlodipine treatment resulted in a decrease in cardiovascular events and overall mortality, and the relevance of an issue related to the best choice of a therapy regimen was confirmed. Comparative prospective studies considering current target blood pressure values and antihypertensive therapy regimens should be conducted.
Download pdf|1,4 МБ
Efremova Yu.E., Kaftanov A.N., Gavrilov D.V., Arutyunov G.P. The results of a retrospective study to evaluate efficiency of combined use of azilsartan medoxomil + amlodipine vs. perindopril + amlodipine in patients with various degrees of hypertension in relation to cardiovascular events (EDARGO-CV). RMJ. 2024;9:7–14. DOI: 10.32364/2225-2282-2024-9-2
Share
Subscribe to our newsletter
Are you interested in digital healthcare and artificial intelligence for medicine? Join our mailing list!